Role of prolonged mitotic checkpoint activation in the formation and treatment of cancer

Future Oncology

Volumn 5, Issue 9, 2009, Pages 1363-1370

  Dalton, W Brian ^a   Yang, Vincent W ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aneuploidy; Antimitotic chemotherapy; Apoptosis; Cell cycle arrest; Centrosomes; Checkpoint; Chromosomal instability; DNA damage; Mitosis; Polypoidy; Tumorigenesis

Indexed keywords

ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; COLCHICINE; EPOTHILONE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NOCODAZOLE; PROTEIN P53; TAXANE DERIVATIVE; VINCA ALKALOID;

ANEUPLOIDY; APOPTOSIS; CANCER CELL; CANCER GENETICS; CANCER GROWTH; CARCINOGENESIS; CELL ACTIVATION; CELL CYCLE ARREST; CELL DIVISION; CELL FATE; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATION; CHROMOSOME CONDENSATION; CHROMOSOME DUPLICATION; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; DISEASE COURSE; DNA DAMAGE; DNA REPAIR; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SYNTHESIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METAPHASE; MITOSIS; NONHUMAN; ONCOGENE; POLYPLOIDY; PRIORITY JOURNAL; PROMETAPHASE; REVIEW; SISTER CHROMATID; DRUG EFFECT; GENETICS; MITOSIS SPINDLE; NEOPLASM;

ANTIMITOTIC AGENTS; HUMANS; MITOSIS; MITOTIC SPINDLE APPARATUS; NEOPLASMS;

EID: 74949115115     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.118     Document Type: Review

References (64)

1. von Hansemann D: Ueber asymmetrische Zellheilteilung in epithelkrebsen und deren biologische bedeutung. Virschows Arch. Pathol. Anat. 119, 299-326 (1890).
2. Dalton WB, Yang VW: Mitotic origins of chromosomal instability in colorectal cancer. Curr. Colorectal Cancer Rep. 3(2), 59-64 (2007).
3. Kops GJ, Weaver BA, Cleveland DW: On the road to cancer: aneuploidy and the mitotic checkpoint. Nat. Rev. Cancer 5(10), 773-785 (2005).
4. Weaver BA, Cleveland DW: Does aneuploidy cause cancer? Curr. Opin. Cell Biol. 18(6), 658-667 (2006).
5. Ganem NJ, Storchova Z, Pellman D: Tetraploidy, aneuploidy and cancer. Curr. Opin. Genet. Dev. 17(2), 157-162 (2007).
6. Rieder CL, Maiato H: Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev. Cell 7(5), 637-651 (2004).
7. Jackson JR, Patrick DR, Dar MM, Huang PS: Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat. Rev. Cancer 7(2), 107-117 (2007).
8. Therman E, Kuhn EM: Mitotic modifications and aberrations in cancer. Crit. Rev. Oncog. 1(3), 293-305 (1989).
9. Yang Z, Loncarek J, Khodjakov A, Rieder CL: Extra centrosomes and/or chromosomes prolong mitosis in human cells. Nat. Cell Biol. 10(6), 748-751 (2008). • Describes that the extra number of chromosomes or centrosomes prolong mitosis in human cells by delaying satisfaction of the spindle assembly checkpoint. This finding may contribute to the elevated mitotic index seen in many tumors.
10. Sisken JE, Bonner SV, Grasch SD, Powell DE, Donaldson ES: Alterations in metaphase durations in cells derived from human tumours. Cell Tissue Kinet. 18(2), 137-146 (1985).
11. Sisken JE, Bonner SV, Grasch SD: The prolongation of mitotic stages in SV40-transformed vs nontransformed human fibroblast cells. J. Cell Physiol. 113(2), 219-223 (1982).
12. Hernando E, Nahle Z, Juan G et al.: Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 430(7001), 797-802 (2004).
13. Sotillo R, Hernando E, Diaz-Rodriguez E et al.: Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell 11(1), 9-23 (2007). • Demonstrates that transient overexpression of the mitotic spindle assembly checkpoint protein, Mad2, in transgenic mice leads to chromosomal instability and a wide variety of neoplasia. The results suggest that prolonged mitosis due to Mad2 overexpression can be an important stimulus in the initiation and progression of different cancer subtypes.
14. Rajagopalan H, Jallepalli PV, Rago C et al.: Inactivation of hCDC4 can cause chromosomal instability. Nature 428(6978), 77-81 (2004).
15. Keck JM, Summers MK, Tedesco D et al.: Cyclin E overexpression impairs progression through mitosis by inhibiting APC(Cdh1). J. Cell Biol. 178(3), 371-385 (2007).
16. Austin KM, Gupta ML, Coats SA et al.: Mitotic spindle destabilization and genomic instability in Shwachman-Diamond syndrome. J. Clin. Invest. 118(4), 1511-1518 (2008).
17. Perez-Moreno M, Song W, Pasolli HA, Williams SE, Fuchs E: Loss of p120 catenin and links to mitotic alterations, inflammation, and skin cancer. Proc. Natl Acad. Sci. USA 105(40), 15399-15404 (2008).
18. Yamauchi T, Ishidao T, Nomura T et al.: A B-Myb complex containing clathrin and filamin is required for mitotic spindle function. EMBO J. 27(13), 1852-1862 (2008).
19. Royle SJ, Bright NA, Lagnado L: Clathrin is required for the function of the mitotic spindle. Nature 434(7037), 1152-1157 (2005).
20. Menssen A, Epanchintsev A, Lodygin D et al.: c-MYC delays prometaphase by direct transactivation of MAD2 and BubR1: identification of mechanisms underlying c-MYC-induced DNA damage and chromosomal instability. Cell Cycle 6(3), 339-352 (2007).
21. Cui Y, Guadagno TM: B-Raf(V600E) signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells. Oncogene 27(22), 3122-3133 (2008).
22. Nguyen CL, Munger K: Human papillomavirus E7 protein deregulates mitosis via an association with nuclear mitotic apparatus protein 1. J. Virol. 83(4), 1700-1707 (2009).
23. Diaz-Rodriguez E, Sotillo R, Schvartzman JM, Benezra R: Hec1 overexpression hyperactivates the mitotic checkpoint and induces tumor formation in vivo. Proc. Natl Acad. Sci. USA 105(43), 16719-16724 (2008).
24. Shi J, Orth JD, Mitchison T: Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. Cancer Res. 68(9), 3269-3276 (2008).
25. Weaver BA, Cleveland DW: Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell 8(1), 7-12 (2005).
26. Gascoigne KE, Taylor SS: Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 14(2), 111-122 (2008). •• Systemically analyzed over 10,000 single cells from 15 cell lines in response to three different classes of antimitotic drug and showed that the variation in cell behavior is far greater than previously recognized, with cells within any given line exhibiting multiple fates. The paper also suggests that accumulation of DNA damage during mitotic arrest may be one cause of a death signal.
27. Thompson SL, Compton DA: Examining the link between chromosomal instability and aneuploidy in human cells. J. Cell Biol. 180(4), 665-672 (2008).
28. Brito DA, Rieder CL: Mitotic checkpoint slippage in humans occurs via cyclin b1 destruction in the presence of an active checkpoint. Curr. Biol. 16(12), 1194-1200 (2006).
29. Allan LA, Clarke PR: Phosphorylation of caspase-9 by CDK1.cyclin B1 protects mitotic cells against apoptosis. Mol. Cell 26(2), 301-310 (2007).
30. Stukenberg PT: Triggering p53 after cytokinesis failure. J. Cell Biol. 165(5), 607-608 (2004).
31. Cross SM, Sanchez CA, Morgan CA et al.: A p53-dependent mouse spindle checkpoint. Science 267(5202), 1353-1356 (1995).
32. Di Leonardo A, Khan SH, Linke SP, Greco V, Seidita G, Wahl GM: DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res. 57(6), 1013-1019 (1997).
33. Vogel C, Kienitz A, Hofmann I, Muller R, Bastians H: Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy. Oncogene 23(41), 6845-6853 (2004).
34. Andreassen PR, Lohez OD, Lacroix FB, Margolis RL: Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1. Mol. Biol. Cell 12(5), 1315-1328 (2001).
35. Minn AJ, Boise LH, Thompson CB: Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. Genes Dev. 10(20), 2621-2631 (1996).
36. Khan SH, Wahl GM: p53 and pRb prevent rereplication in response to microtubule inhibitors by mediating a reversible G1 arrest. Cancer Res. 58(3), 396-401 (1998).
37. Lanni JS, Jacks T: Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol. Cell. Biol. 18(2), 1055-1064 (1998).
38. Stewart ZA, Leach SD, Pietenpol JA: p21(Waf1/Cip1) inhibition of cyclin E/Cdk2 activity prevents endoreduplication after mitotic spindle disruption. Mol. Cell. Biol. 19(1), 205-215 (1999).
39. Galmarini CM, Falette N, Tabone E et al.: Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicity. Br. J. Cancer 85(6), 902-908 (2001).
40. Kienitz A, Vogel C, Morales I, Muller R, Bastians H: Partial downregulation of MAD1 causes spindle checkpoint inactivation and aneuploidy, but does not confer resistance towards taxol. Oncogene 24(26), 4301-4310 (2005).
41. Wu GS, El-Diery WS: p53 and chemosensitivity. Nat. Med. 2(3), 255-256 (1996).
42. Yamaguchi H, Chen J, Bhalla K, Wang HG: Regulation of Bax activation and apoptotic response to microtubule-damaging agents by p53 transcription-dependent and -independent pathways. J. Biol. Chem. 279(38), 39431-39437 (2004).
43. Woods CM, Zhu J, McQueney PA, Bollag D, Lazarides E: Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol. Med. 1(5), 506-526 (1995).
44. Strobel T, Swanson L, Korsmeyer S, Cannistra SA: BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc. Natl Acad. Sci. USA 93(24), 14094-14099 (1996).
45. Wahl AF, Donaldson KL, Fairchild C et al.: Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat. Med. 2(1), 72-79 (1996).
46. Bunz F, Fauth C, Speicher MR et al.: Targeted inactivation of p53 in human cells does not result in aneuploidy. Cancer Res. 62(4), 1129-1133 (2002).
47. Ganem NJ, Godinho SA, Pellman D: A mechanism linking extra centrosomes to chromosomal instability. Nature 460(7252), 278-282 (2009). •• Demonstrates that extra centrosomes can promote chromosome seggregation during bipolar cell division due to merotelic kninetochore-microtubule attachment errors. The study therefore provides a direct mechanistic link between extra centrosomes and chromosomal instability in solid tumors.
48. Weaver BA, Silk AD, Montagna C, Verdier-Pinard P, Cleveland DW: Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 11(1), 25-36 (2007). • This study shows that cells and mice with reduced levels of the mitosis-specific centromere-linked motor protein, CENP-E, develop aneuploidy and chromosomal instability. However, in some cases, an increased rate of aneuploidy is an inhibitor of tumorigenesis. These findings suggest that aneuploidy has both an oncogenic and tumor suppressive effect.
49. van Deursen JM: Rb loss causes cancer by driving mitosis mad. Cancer Cell 11(1), 1-3 (2007).
50. Fujiwara T, Bandi M, Nitta M, Ivanova EV, Bronson RT, Pellman D: Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature 437(7061), 1043-1047 (2005).
51. Duelli DM, Padilla-Nash HM, Berman D, Murphy KM, Ried T, Lazebnik Y: A virus causes cancer by inducing massive chromosomal instability through cell fusion. Curr. Biol. 17(5), 431-437 (2007).
52. Roh M, Franco OE, Hayward SW, van der Meer R, Abdulkadir SA: A role for polyploidy in the tumorigenicity of Pim-1-expressing human prostate and mammary epithelial cells. PLoS ONE 3(7), E2572 (2008).
53. Rajagopalan H, Nowak MA, Vogelstein B, Lengauer C: The significance of unstable chromosomes in colorectal cancer. Nat. Rev. Cancer 3(9), 695-701 (2003).
54. Castedo M, Coquelle A, Vivet S et al.: Apoptosis regulation in tetraploid cancer cells. EMBO J. 25(11), 2584-2595 (2006).
55. Loeb KR, Kostner H, Firpo E et al.: A mouse model for cyclin E-dependent genetic instability and tumorigenesis. Cancer Cell. 8(1), 35-47 (2005).
56. Wong C, Stearns T: Mammalian cells lack checkpoints for tetraploidy, aberrant centrosome number, and cytokinesis failure. BMC Cell Biol. 6(1), 6 (2005).
57. Dalton WB, Nandan MO, Moore RT, Yang VW: Human cancer cells commonly acquire DNA damage during mitotic arrest. Cancer Res. 67(24), 11487-11492 (2007). •• Describes mitotic arrest as a novel source of DNA damage in human cells and can lead to karyotype alterations. The study also suggests that mitotic arrest may promote tumorigenesis and antimitotic toxicity by provoking DNA damage.
58. Quignon F, Rozier L, Lachages AM, Bieth A, Simili M, Debatisse M: Sustained mitotic block elicits DNA breaks: one-step alteration of ploidy and chromosome integrity in mammalian cells. Oncogene 26(2), 165-172 (2007).
59. Stevens JB, Liu G, Bremer SW et al.: Mitotic cell death by chromosome fragmentation. Cancer Res. 67(16), 7686-7694 (2007).
60. Swanton C, Nicke B, Schuett M et al.: Chromosomal instability determines taxane response. Proc. Natl Acad. Sci. USA 106(21), 8671-8676 (2009). • Identified a set of genes, many of which are involved in DNA damage repair, that are repressed in multiple cancer cell lines with chromosomal instability in response to antimitotic agent-induced cell death. Overexpression of these genes is asociated with poor prognosis, suggesting that they are invoved in the survival of aneuploid cells.
61. Farmer H, McCabe N, Lord CJ et al.: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035), 917-921 (2005).
62. Yeasmin S, Nakayama K, Ishibashi M et al.: Therapy-related myelodysplasia and acute myeloid leukemia following paclitaxel- and carboplatin-based chemotherapy in an ovarian cancer patient: a case report and literature review. Int. J. Gynecol. Cancer 18(6), 1371-1376 (2008).
63. Seymour JF, Juneja SK, Campbell LJ, Ellims PH, Estey EH, Prince HM: Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy. Leukemia 13(11), 1735-1740 (1999).
64. Dissing M, Le Beau MM, Pedersen-Bjergaard J: Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors? J. Clin. Oncol. 16(5), 1890-1896 (1998).